Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

Core Viewpoint - Rakovina Therapeutics Inc. plans to amend the terms of its outstanding convertible debentures and warrants, subject to approval from the TSX Venture Exchange and the requisite majority of holders [1][3]. Convertible Debenture Amendments - The company intends to amend its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000, issued on May 29, 2023 [2][3]. - Proposed amendments include extending the maturity date from November 29, 2025, to June 6, 2028, reducing the conversion price from $2.00 to $1.00 per common share, eliminating any redemption premium, and stipulating that interest accrued will be payable on the maturity date [7]. Warrant Amendments - The company plans to amend the terms of 19,200,000 outstanding common share purchase warrants, which were issued in a private placement between June 26, 2024, and July 26, 2024 [5][6]. - Proposed changes include reducing the exercise price from $2.00 to $0.75 per common share and shortening the term from three years to thirty days from the date of Exchange approval [6]. Related Party Transactions - Certain directors of the company hold a principal amount of $100,000 in convertible debentures, representing approximately 6.9% of the outstanding amount, which qualifies as a related party transaction [4]. - Director Jeffrey Bacha holds 100,000 warrants, approximately 0.5% of the outstanding warrants, also constituting a related party transaction [8]. Company Overview - Rakovina Therapeutics is a biopharmaceutical research company focused on developing innovative cancer treatments using unique technologies for targeting the DNA-damage response, powered by artificial intelligence [10].